JP5208962B2 - 二環式ピリミジノンおよびその使用 - Google Patents

二環式ピリミジノンおよびその使用 Download PDF

Info

Publication number
JP5208962B2
JP5208962B2 JP2009541695A JP2009541695A JP5208962B2 JP 5208962 B2 JP5208962 B2 JP 5208962B2 JP 2009541695 A JP2009541695 A JP 2009541695A JP 2009541695 A JP2009541695 A JP 2009541695A JP 5208962 B2 JP5208962 B2 JP 5208962B2
Authority
JP
Japan
Prior art keywords
alkyl
hydroxy
oxo
carboxylic acid
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009541695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513322A5 (OSRAM
JP2010513322A (ja
Inventor
エリック・デイル・ジョーンズ
ジョナサン・アラン・ビクター・コーツ
デイビッド・イアン・ローズ
ジョン・ジョセフ・デッドマン
ニコラス・アンドリュー・バンデグラフ
リサ・ジェーン・ウィンフィールド
ネーラナット・ティエントン
ウィリアム・イッサ
ニール・チョイ
キャサリン・マクファーレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tali Digital Ltd
Original Assignee
Avexa Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006907283A external-priority patent/AU2006907283A0/en
Application filed by Avexa Ltd filed Critical Avexa Ltd
Publication of JP2010513322A publication Critical patent/JP2010513322A/ja
Publication of JP2010513322A5 publication Critical patent/JP2010513322A5/ja
Application granted granted Critical
Publication of JP5208962B2 publication Critical patent/JP5208962B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2009541695A 2006-12-22 2007-12-21 二環式ピリミジノンおよびその使用 Expired - Fee Related JP5208962B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2006907283 2006-12-22
AU2006907283A AU2006907283A0 (en) 2006-12-22 Bicyclic pyrimidinones and uses thereof
AU2007902479 2007-05-09
AU2007902479A AU2007902479A0 (en) 2007-05-09 Bicyclic pyrimidinones and uses thereof (2)
AU2007903401 2007-06-25
AU2007903401A AU2007903401A0 (en) 2007-06-25 Bicyclic pyrimidinodes and uses thereof (3)
AU2007904114 2007-07-31
AU2007904114A AU2007904114A0 (en) 2007-07-31 Bicyclic pyrimidinones and uses thereof (4)
PCT/AU2007/001980 WO2008077188A1 (en) 2006-12-22 2007-12-21 Bicyclic pyrimidinones and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010129801A Division JP2010222370A (ja) 2006-12-22 2010-06-07 二環式ピリミジノンおよびその使用

Publications (3)

Publication Number Publication Date
JP2010513322A JP2010513322A (ja) 2010-04-30
JP2010513322A5 JP2010513322A5 (OSRAM) 2010-06-24
JP5208962B2 true JP5208962B2 (ja) 2013-06-12

Family

ID=39562030

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009541695A Expired - Fee Related JP5208962B2 (ja) 2006-12-22 2007-12-21 二環式ピリミジノンおよびその使用
JP2010129801A Withdrawn JP2010222370A (ja) 2006-12-22 2010-06-07 二環式ピリミジノンおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010129801A Withdrawn JP2010222370A (ja) 2006-12-22 2010-06-07 二環式ピリミジノンおよびその使用

Country Status (15)

Country Link
US (3) US8143268B2 (OSRAM)
EP (2) EP2114903B1 (OSRAM)
JP (2) JP5208962B2 (OSRAM)
KR (2) KR20090097194A (OSRAM)
CN (1) CN101880280B (OSRAM)
AR (2) AR064517A1 (OSRAM)
AT (1) ATE496898T1 (OSRAM)
AU (2) AU2007336703B9 (OSRAM)
BR (2) BRPI0720564A2 (OSRAM)
CA (1) CA2673183C (OSRAM)
DE (1) DE602007012308D1 (OSRAM)
DK (1) DK2114903T3 (OSRAM)
MX (1) MX2009006764A (OSRAM)
NZ (1) NZ577491A (OSRAM)
WO (1) WO2008077188A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526248A (ja) * 2008-07-02 2011-10-06 アベキサ・リミテッド 抗ウイルス特性を有する化合物
JP2011526246A (ja) * 2008-07-02 2011-10-06 アベキサ・リミテッド チアゾピリミジノンおよびその使用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5592360B2 (ja) * 2008-07-02 2014-09-17 アベキサ・リミテッド イミダゾピリミジノンおよびその使用
CN102336751A (zh) * 2010-07-16 2012-02-01 爱维艾珂瑟有限公司 新型抗病毒剂
JP6448647B2 (ja) 2013-09-12 2019-01-09 アリオス バイオファーマ インク． アザ−ピリドン化合物およびその用途
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
MX383931B (es) 2015-03-11 2025-03-14 Janssen Biopharma Inc Compuestos de aza-piridona y usos de estos.
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
CN108697709A (zh) 2015-12-10 2018-10-23 Ptc医疗公司 用于治疗亨廷顿病的方法
AU2017363369A1 (en) 2016-11-28 2019-05-30 Ptc Therapeutics, Inc Methods for modulating RNA splicing
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
US11608501B2 (en) 2017-06-14 2023-03-21 Ptc Therapeutics, Inc. Methods for modifying RNA splicing
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
AU2020394867A1 (en) 2019-12-02 2022-05-26 Storm Therapeutics Limited Polyheterocyclic compounds as METTL3 inhibitors
US12070445B2 (en) * 2021-08-27 2024-08-27 Wisconsin Alumni Research Foundation System and assay for monitoring production/release of membrane-lytic toxins in bacteria and compounds for modulating same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002241459A1 (en) 2000-09-20 2002-06-11 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
AR042095A1 (es) 2002-11-20 2005-06-08 Japan Tobacco Inc Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih
DK1697343T3 (da) 2003-12-18 2009-10-05 Tibotec Pharm Ltd Aminobenzimidazoler og benzimidazoler som inhibitorer af replikation af respiratorisk syncytialvirus
TW200526635A (en) * 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
CN101146811B (zh) * 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
EP1937678B1 (en) * 2005-10-04 2011-07-27 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526248A (ja) * 2008-07-02 2011-10-06 アベキサ・リミテッド 抗ウイルス特性を有する化合物
JP2011526246A (ja) * 2008-07-02 2011-10-06 アベキサ・リミテッド チアゾピリミジノンおよびその使用

Also Published As

Publication number Publication date
HK1131615A1 (en) 2010-01-29
AU2007336703B2 (en) 2012-04-12
AR077043A2 (es) 2011-07-27
EP2114903A1 (en) 2009-11-11
US8143268B2 (en) 2012-03-27
CA2673183A1 (en) 2008-07-03
AU2010201160A1 (en) 2010-04-15
CN101880280A (zh) 2010-11-10
EP2114903A4 (en) 2009-12-30
CN101880280B (zh) 2014-07-16
AU2007336703A1 (en) 2008-07-03
BRPI0722411A2 (pt) 2012-06-05
AR064517A1 (es) 2009-04-08
ATE496898T1 (de) 2011-02-15
DK2114903T3 (da) 2011-04-18
EP2269992A1 (en) 2011-01-05
JP2010222370A (ja) 2010-10-07
US20100168063A1 (en) 2010-07-01
KR20100049698A (ko) 2010-05-12
US20110009366A1 (en) 2011-01-13
BRPI0720564A2 (pt) 2011-08-16
US8207334B2 (en) 2012-06-26
WO2008077188A1 (en) 2008-07-03
MX2009006764A (es) 2009-11-26
US8859563B2 (en) 2014-10-14
DE602007012308D1 (de) 2011-03-10
CA2673183C (en) 2014-06-10
NZ577491A (en) 2011-06-30
EP2114903B1 (en) 2011-01-26
JP2010513322A (ja) 2010-04-30
KR20090097194A (ko) 2009-09-15
US20120232035A1 (en) 2012-09-13
AU2007336703B9 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
JP5208962B2 (ja) 二環式ピリミジノンおよびその使用
JP5535204B2 (ja) 抗ウイルス特性を有する化合物
JP2003321472A (ja) Ｇｒｋ阻害剤
JP2012514044A (ja) Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
CZ194994A3 (en) Piperazine and piperidine derivatives, process of their preparation and pharmaceutical compositions containing thereof
CA2729656A1 (en) Imidazopyrimidinones and uses thereof
EP3328840A1 (en) Substituted triazolo bicyclic compounds as pde2 inhibitors
CN101627019A (zh) 双环嘧啶酮以及其应用
ES2358550T3 (es) Pirimidinonas bicíclicas y sus usos.
HK1131615B (en) Bicyclic pyrimidinones and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130220

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160301

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees